AbCheck s.r.o. Receives Grant to Further Develop a Discovery Technology for Functional Antibodies using Microfluidics
AbCheck announced a grant from the Ministry of Industry and Trade of the Czech Republic, valued at up to €1.44 million over the next 3 years. This funding supports the development of a microfluidic system for discovering rare therapeutic antibodies. The innovative technology allows screening millions of droplets containing antibody-expressing cells daily, enhancing the discovery of functional antibodies critical for cancer treatments. The grant will expedite the creation of specialized bioassays, reinforcing AbCheck's commitment to advanced antibody discovery.
- Secured a grant of up to €1.44 million for antibody discovery.
- Innovative microfluidic technology enables high-throughput screening of antibody-producing cells.
- Potential for expedited development of unique antibodies for cancer therapies.
- None.
Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today announced that it has been awarded a grant supporting the further development of a unique approach for the discovery of functional antibodies using a microfluidic system. The grant was awarded from the Ministry of Industry and Trade of the Czech Republic as the managing authority Operational Program, Enterprise and Innovation for Competitiveness.
The grant, entitled Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect warrants up to
"We are delighted that the Ministry of Industry and Trade of the Czech Republic has realized the potential of this novel approach for the discovery of antibodies and subsequently awarded AbCheck with the grant," stated Volker Lang, Ph.D, Managing Director of AbCheck.
"We have been developing the microfluidic system for 2.5 years and have progressed to a stage where we can identify functional antibodies with very specialized properties,” stated Oleh Petriv, Ph.D, Head of New Technologies at AbCheck. “This grant will enable AbCheck to significantly speed up the development of a differentiated arsenal of bioassays to discover very rare and unique antibodies for emerging cancer treatments.”
About AbCheck
AbCheck s.r.o. discovers and optimizes human antibodies leveraging several proprietary platforms including in vitro and in vivo technologies. We use phage/yeast display libraries (AbSieve®), mass humanization and antibody optimization (AbAccel®) and a microfluidic platform to provide high quality leads. Flexibly adapting to our partners’ needs, we offer a variety of business models, including deals without royalties. AbCheck has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH. For more information, please visit http://abcheck.eu.
Contact Information:
AbCheck
Dr. Volker Lang
Managing Director
+420 378 051500
v.lang@abcheckantibodies.eu
FAQ
What grant did AbCheck receive?
How will the grant impact AbCheck's antibody discovery?
What is the value of the grant awarded to AbCheck?
What is the purpose of the microfluidic technology developed by AbCheck?
How long will the grant support AbCheck's projects?
